Drug profile · INN
thiamylal sodium
SURITAL
thiamylal sodium (SURITAL) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: injection. Current US regulatory status: approved.
Drug details — thiamylal sodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
thiamylal sodium (SURITAL) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA-A receptor; anion channel positive allosteric modulator
Primary target: GABA-A receptor; anion channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is thiamylal sodium?
thiamylal sodium (SURITAL) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for thiamylal sodium?
SURITAL is a marketed brand name for thiamylal sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of thiamylal sodium?
thiamylal sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.